Abstract:Objective:To evaluate the results of neuroblastoma (NB) based upon risk-adapted therapy.Methods:From September 2002 to December 2018, clinical data were reviewed for 483 newly diagnosed NB patients aged ≤18 years based on risk-adapted therapy. They were stratified into low, intermediate and high-risk groups by age, stage, histological category and MYCN status. There were 290 males and 193 females with a median diagnostic age of 3.5 years (7 days to 18 years). The stages were 1 (n=19) , 2 (n=25) , 3 (n=95) , 4 (n=334) and 4S (n=10). Surgery alone or surgery plus low intensive chemotherapy for low-risk group (n=46, 9.5%) ; Surgery plus moderate intensive chemotherapy with or without radiotherapy for intermediate-risk group (n=102, 21.1%) ; For high-risk group (n=335, 69.4%) , before 2013, the treatment strategies included 8 cycles of alternating chemotherapy of cyclophosphamide (CTX) + vincristine (VCR) + pirarubicin (THP) and cisplatin (DDP) + etoposide (VP16) , surgery, with or without autologous hematopoietic stem cell transplantation (ASCT) , radiotherapy, with or without biotherapy and isotretinoin maintenance therapy for 1 year; after 2013, 8 cycles of alternating chemotherapy of CTX + VCR + THP and VP16 + ifosfamide + DDP protocol, surgery, radiotherapy, with or without biological therapy and oral maintenance chemotherapy drugs for 1 year. Recurrent patients received salvage therapy.Results:MYCN amplification was 22.4 % (72/322) in all groups and 33.8%(72/213) in high-risk group. ASCT was performed for only 15 cases. During a median follow-up period of 38(2.5-208) months, 3-year event-free survival (EFS) and overall survival (OS) were (86.5±5.1) % and 100% for low-risk group ; (79.1±4.3)% and (89.2±3.3) % for intermediate-risk group ; (30.6±2.7)% and (60.3±2.9)% for high-risk group respectively. Univariate survival analysis of 335 high-risk patients indicated that stage 4 and chemotherapy alone were poor prognostic factors for EFS/OS. Multivariate survival analysis showed that stage 4 and chemotherapy alone were independent adverse prognostic factors for EFS in high-risk NB patients while stage 4, chemotherapy alone and primary abdominal lesions were independent adverse prognostic factors for OS in high-risk NB patients. The 3-year EFS for MYCN positive high-risk patients was (27.4±6.3) % and for MYCN negative high-risk patients (36.7±4.4) % and the inter-group difference was statistically significant ( P=0.049). The 3-year EFS for MYCN positive high-risk patients with stage 4 was (18.7±6.7) % and for MYCN positive high-risk patients with stage 3/4S was (49.4±13.1) % and the inter-group difference was statistically significant ( P=0.009). In high-risk complete/partial remission patients without ASCT, 3-year EFS of oral isotretinoin maintenance therapy was (28.0±5.1)% while 3- year EFS of oral chemotherapy maintenance therapy was (42.1±5.1)% and the inter-group difference was statistically significant ( P=0.019). In high-risk patients, 3-year EFS for the therapeutic model of chemotherapy + surgery + radiotherapy was 37.1% , 19.0% for chemotherapy + surgery and 7.7% for chemotherapy alone. And the inter-group differences were statistically significant ( P<0.001). The 3-year EFS in high-risk group was (21.5±4.1 ) % before 2013 and (34.9±3.6) % after 2013. And the inter-group difference was statistically significant ( P=0.004) ; 3- year OS in high-risk group was (47.7±4.9)% before 2013 and (66.7±3.6) % after 2013. And the inter-group difference was statistically significant ( P<0.001). Conclusions:NB may be stratified into low, intermediate and high-risk groups based upon age, stage, histological category and MYCN status. For risk-adapted therapy, low and intermediate groups have better survival. High-risk patients have poor survival and new therapy should be explored. Salvage therapy for recurrent NB offers a survival benefit.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era

Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification

Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report

MYCN amplification and International Neuroblastoma Risk Group stratification on fine-needle aspiration biopsy and their correlation to survival in neuroblastoma

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification

Outcome analysis of neuroblastoma based upon risk-adapted therapy: a report of 483 cases

Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma

MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma

Neonatal Neuroblastoma: the Controversy of Treatment, Clinical Features and Outcome

Clinical Evaluation of Integrated Panel Testing by Next-Generation Sequencing for Somatic Mutations in Neuroblastomas with Mycn Unamplification

Novel sex-biased outcomes in neuroblastoma are associated with distinct gene expression and chromosomal loss patterns.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma

Clinical Outcomes of Children with Neuroblastoma under Multidisciplinary Treatment

Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma